alexa Animal Models Of Human Cancer Vaccines
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd World Congress on Cancer Science & Therapy
October 21-23, 2013 DoubleTree by Hilton Hotel San Francisco Airport, CA, USA

Dorothee Herlyn
ScientificTracks: J Cancer Sci Ther
DOI: 10.4172/1948-5956.S1.028
Abstract
This lecture will critically review clinical trials conducted with various forms of cancer vaccines over more than 3 decades. The vaccines include tumor cells, peptides, proteins, fusion proteins, carbohydrates, and viral or bacterial vectors expressing tumor antigens. Possible explanations for why only one vaccine has been approved for patients? treatment by the FDA will be discussed with emphasis on failure of most vaccines to activate therapeutic anti-tumor immunity. Recently, immune checkpoint blockade has proven effective to activate therapeutic immune responses in cancer patients by removing blockade of immune effector cell activity with antibodies. The antibodies studied the most clinically thus far are directed to the inhibitory molecules CTLA-4 or PD-1 which are expressed by lymphocytes and/or antigen-presenting cells. Novel avenues for combination cancer treatments capitalize on the complementarities of immune checkpoint blockade and cancer vaccines as the induction of tumor- associated immunity is greatly aided by activation of adaptive and innate immunity after removal of immune effector cell blockade. Clinical trials with such combination therapies have just begun.
Biography
Dorothee Herlyn has studied cancer immunotherapy for 36+ years during that time she has authored more than 170 peer-reviewed reports. She has served on the editorial boards of 8 cancer-related international journals, including Cancer Research, Cancer Immunology & Immunotherapy and Cancer Gene Therapy . Herlyn has been a member of 6 professional societies and has served on numerous review committees for the NCI, including Subcommittee D Initial Review Group, and Experimental Immunology Study Section. She is currently chair of the grant review committee for the Melanoma Research Foundation.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords